Nat. Med. 10, 145–147 (2004).
The complete trial schema was omitted from the article. The protocol is outlined below.Table 1
Additional information
The online version of the original article can be found at 10.1038/nm988
Rights and permissions
About this article
Cite this article
Willett, C., Boucher, Y., di Tomaso, E. et al. Correction: Corrigendum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 649 (2004). https://doi.org/10.1038/nm0604-649c
Issue Date:
DOI: https://doi.org/10.1038/nm0604-649c
- Springer Nature America, Inc.